MAPT and Alzheimer disease: By diluting plasma into CSF ex vivo to mimic BBB dysfunction and breakdown, we demonstrate that with increasing plasma levels there is a corresponding reduction of tau and synaptic proteins in AD CSF, in part through thrombin proteolytic activity.